CPC A61K 38/1774 (2013.01) [A61K 39/4613 (2023.05); A61K 39/4631 (2023.05); A61K 39/4644 (2023.05); A61K 39/464411 (2023.05); A61K 2239/48 (2023.05)] | 22 Claims |
1. A composition comprising a genetically modified T cell or Natural Killer (NK) cell, wherein the modified T cell or NK cell expresses a chimeric antigen receptor (CAR) that specifically targets a tumor-associated antigen, wherein the CAR comprises 1) a first amino acid sequence comprising an antigen binding domain and 2) a second amino acid sequence comprising a CD8 hinge domain, a CD28 transmembrane domain, and an FcεRIγ signaling domain, wherein the second amino acid sequence has at least 95% sequence identity to amino acids 268-401 of SEQ ID NO: 16.
|
12. A method for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both, in a subject in need thereof, the method comprising: administering to the subject, intravenously or by injection, 1) a therapeutically effective amount of a genetically modified NK cell comprising a) a chimeric antigen receptor (CAR) that specifically binds CD33, wherein the CAR comprises a first amino acid sequence comprising a CD33 binding domain and a second amino acid sequence comprising a CD8 hinge domain, a CD28 transmembrane domain, and an FcεRIγ signaling domain, wherein the second amino acid sequence has at least 95% sequence identity to amino acids 268-401 of SEQ ID NO: 16, and b) a CD16 receptor; and 2) a therapeutically effective amount of an antibody.
|
17. A composition comprising 1) an effective amount of a genetically modified NK cell comprising a) a chimeric antigen receptor (CAR) that specifically binds CD33, wherein the CAR comprises a first amino acid sequence comprising a CD33 binding domain and a second amino acid sequence comprising a CD8 hinge domain, a CD28 transmembrane domain, and an FcεRIγ signaling domain, wherein the second amino acid sequence has at least 95% sequence identity to amino acids 268-401 of SEQ ID NO: 16, and b) a CD16 receptor; and 2) an effective amount of an antibody.
|